

Resource Summary Report

Generated by [NIF](#) on Sep 21, 2026

SEM

RRID:CVCL_0095

Type: Cell Line

Proper Citation

RRID:CVCL_0095

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0095

Proper Citation: RRID:CVCL_0095

Description: Cell line SEM is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Childhood B acute lymphoblastic leukemia

Defining Citation: [PMID:7794749](#), [PMID:8199015](#), [PMID:9067587](#), [PMID:9881706](#), [PMID:14671638](#), [PMID:20215515](#), [PMID:21552520](#), [PMID:22460905](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31160637](#), [PMID:31978347](#), [PMID:35354797](#)

Comments: Population: Caucasian., Part of: LL-100 blood cancer cell line panel., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SEM

Cross References: EFO:EFO_0002326, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-7721, ArrayExpress:E-MTAB-7722, BioGRID_ORCS_Cell_line:1548, BioSample:SAMN03473532, BioSample:SAMN10988273, cancercellines:CVCL_0095, Cell_Model_Passport:SIDM01424, ChEMBL-Cells:ChEMBL4295399, ChEMBL-Targets:ChEMBL4296493, Cosmic:1130254, Cosmic:2491076, Cosmic:2542839, DepMap:ACH-000782, DSMZ:ACC-546, DSMZCellDive:ACC-546, GEO:GSM887563,

GEO:GSM888646, GEO:GSM5137743, GEO:GSM5137744, IARC_TP53:28231, IGRhCellID:SEM, LiGeA:CCLE_736, PharmacDB:SEM_1363_2019, PRIDE:PXD023662, Progenetix:CVCL_0095, PubChem_Cell_line:CVCL_0095, Wikidata:Q54952795

ID: CVCL_0095

Record Creation Time: 20220427T221537+0000

Record Last Update: 20260920T005729+0000

Ratings and Alerts

No rating or validation information has been found for SEM.

No alerts have been found for SEM.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 24 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#).

Kunzmann GB, et al. (2026) Dynamic UFMylation governs cellular fitness by coordinating multi-organelle proteostasis. bioRxiv : the preprint server for biology.

Ng HL, et al. (2026) BCR::ABL1-Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B-ALL Cells to Enhancer-Targeting Drugs. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(25), e17231.

Jenkins TW, et al. (2025) Highly specific Immunoproteasome inhibitor M3258 induces proteotoxic stress and apoptosis in KMT2A::AFF1 driven acute lymphoblastic leukemia. Scientific reports, 15(1), 17284.

Huang Z, et al. (2025) Enhancing Anti-Tumor Effects of Engineered Extracellular Vesicles via Endocytosis Route Switching and Interferon Response Suppression. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e15472.

L????nd F, et al. (2025) DLBCL Cells Emerge after CD19 CAR T Cells with Cross-Antigen Resistance and a Gene Signature Predictive of Clinical CAR T-cell Response. Blood cancer discovery, 6(6), 580.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. Cancer discovery.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. *EBioMedicine*, 118, 105822.

Sharma G, et al. (2025) IGF2BP3 redirects glycolytic flux to promote one-carbon metabolism and RNA methylation. *Cell reports*, 116330.

Brock L, et al. (2025) KMT2A degradation is observed in decitabine-responsive acute lymphoblastic leukemia cells. *Molecular oncology*, 19(5), 1404.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Hamley JC, et al. (2023) Determining chromatin architecture with Micro Capture-C. *Nature protocols*.

Pillsbury CE, et al. (2023) Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia. *Cancer research communications*, 3(7), 1248.

Barnett KR, et al. (2023) Epigenomic mapping reveals distinct B cell acute lymphoblastic leukemia chromatin architectures and regulators. *Cell genomics*, 3(12), 100442.

Downes DJ, et al. (2022) Capture-C: a modular and flexible approach for high-resolution chromosome conformation capture. *Nature protocols*, 17(2), 445.

Tsuzuki H, et al. (2022) Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. *Oncotarget*, 13, 1359.

Pal D, et al. (2022) hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukemia. *Cell reports. Medicine*, 3(8), 100717.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Qi D, et al. (2022) JMJD1C-regulated lipid synthesis contributes to the maintenance of MLL-rearranged acute myeloid leukemia. *Leukemia & lymphoma*, 63(9), 2149.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. *Molecular cell*, 81(17), 3604.